摘要
目的:使用胶质瘤可溶性抗原(CSA)联合超抗原SEC刺激外周血淋巴细胞,诱导产生杀瘤性免疫细胞,对胶质瘤细胞进行杀伤,探讨肿瘤免疫治疗新方法。方法:提取健康人外周血淋巴细胞,体外培养,并经GSA、超抗原SEC联合处理。流式细胞术(FCM)和细胞毒试验测定效应细胞表型和杀伤活性。结果:经GSA、超抗原SEC联合刺激的淋巴细胞组增殖活性最强,于72h达到高峰,并且上调CD8+T细胞群,联合刺激诱导的效应细胞对靶细胞杀伤活性显著高于单纯淋巴细胞组(P<0.05)。结论:GSA与SEC联合应用诱导的效应细胞增殖快,细胞毒活性高,对抗原来源肿瘤细胞具有选择性杀伤作用。该实验研究为肿瘤免疫治疗提供了新的思路。
Objective： To develop tumor-killing immune cells from peripheral blood lymphocytes using glioma associated Ag （GSA） and superantigen SEC and to explore a new method for immunotherapy. Methods： Lymphocytes were isolated from peripheral blood of healthy people and were then treated with GSA and superantigen SEC in vitro. Phenotypes and cytotoxic activity of the effec- tor cells were measured by flow cytometry and cytotoxic assay. Results： The lymphocytes stimulated by GSA and SEC showed more proliferative activity than the control groups, with a peak effect at 72 h, and showed an increased proportion of CD8 ＋ T cells. Co-stim- ulated effector cells had higher cytotoxic activity against target cells than the control group （ P 〈 0.05 ）. Conelusion： The effector cells induced by GSA and SEC have more rapid proliferation, higher cytotoxicity, and selective cytotoxicity against the tumor cells that ini- tially produced the GSA. This study provides a new way of thinking for the development of immunotherapy treatment.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2011年第6期301-303,共3页
Chinese Journal of Clinical Oncology
基金
河北省科技支撑计划项目基金资助(编号:09276418D-18)
